Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash from Operations (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Cash from Operations for 16 consecutive years, with 2530000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 31.25% to 2530000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 15757000.0, a 40.39% decrease, with the full-year FY2024 number at 10600000.0, up 17.52% from a year prior.
  • Cash from Operations was 2530000.0 for Q3 2025 at Plus Therapeutics, up from 5798000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1150000.0 in Q2 2024 to a low of 6172000.0 in Q1 2025.
  • A 5-year average of 3370562.5 and a median of 2892000.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 58.6% in 2024, then crashed 404.17% in 2025.
  • Plus Therapeutics' Cash from Operations stood at 3006000.0 in 2021, then grew by 25.68% to 2234000.0 in 2022, then grew by 15.8% to 1881000.0 in 2023, then surged by 33.17% to 1257000.0 in 2024, then crashed by 101.27% to 2530000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Cash from Operations are 2530000.0 (Q3 2025), 5798000.0 (Q2 2025), and 6172000.0 (Q1 2025).